We anticipate that the use of selective CA IX/XII inhibitors, such as SLC-0111, will be beneficial in combination with chemo-, radiation-, and immunotherapies to eliminate resistant cancer cell populations and for maximum durable suppression of tumor growth and metastasis. The gene discussed is CA9; the disease is neoplasm.